Leerink Partnrs Has Bullish Estimate for RYTM Q3 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Investment analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 5th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings per share of ($0.86) for the quarter, up from their prior forecast of ($0.98). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. Leerink Partnrs also issued estimates for Rhythm Pharmaceuticals’ Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.41) EPS, Q1 2026 earnings at ($1.06) EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.71) EPS and FY2026 earnings at ($3.66) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). Rhythm Pharmaceuticals had a negative return on equity of 1,831.43% and a negative net margin of 117.13%. The firm had revenue of $48.50 million for the quarter, compared to analysts’ expectations of $43.72 million. During the same quarter in the prior year, the business earned ($0.55) EPS. The company’s quarterly revenue was up 66.8% compared to the same quarter last year.

Other analysts have also recently issued reports about the company. Leerink Partners started coverage on Rhythm Pharmaceuticals in a research report on Monday, July 7th. They set an “outperform” rating and a $88.00 price objective for the company. The Goldman Sachs Group started coverage on Rhythm Pharmaceuticals in a research report on Thursday, July 10th. They set a “buy” rating and a $97.00 price objective for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $109.00 price objective (up from $100.00) on shares of Rhythm Pharmaceuticals in a research report on Tuesday. JMP Securities increased their price objective on Rhythm Pharmaceuticals from $130.00 to $135.00 and gave the stock a “market outperform” rating in a research report on Wednesday. Finally, Wall Street Zen raised Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, July 26th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $101.57.

Rhythm Pharmaceuticals Trading Down 0.5%

Rhythm Pharmaceuticals stock opened at $91.98 on Friday. Rhythm Pharmaceuticals has a twelve month low of $43.57 and a twelve month high of $94.80. The stock has a 50 day moving average of $75.37 and a two-hundred day moving average of $63.68. The stock has a market capitalization of $6.11 billion, a price-to-earnings ratio of -30.56 and a beta of 2.38.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Federated Hermes Inc. raised its holdings in Rhythm Pharmaceuticals by 2.7% during the first quarter. Federated Hermes Inc. now owns 1,591,871 shares of the company’s stock worth $84,321,000 after purchasing an additional 42,236 shares during the last quarter. Driehaus Capital Management LLC raised its holdings in Rhythm Pharmaceuticals by 12.9% during the first quarter. Driehaus Capital Management LLC now owns 1,458,022 shares of the company’s stock worth $77,231,000 after purchasing an additional 167,047 shares during the last quarter. Westfield Capital Management Co. LP acquired a new position in Rhythm Pharmaceuticals during the first quarter worth $71,038,000. Geode Capital Management LLC raised its holdings in Rhythm Pharmaceuticals by 1.9% during the second quarter. Geode Capital Management LLC now owns 1,311,253 shares of the company’s stock worth $82,868,000 after purchasing an additional 24,085 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in Rhythm Pharmaceuticals by 103.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company’s stock worth $68,309,000 after purchasing an additional 621,432 shares during the last quarter.

Insiders Place Their Bets

In other news, insider Alastair Garfield sold 1,319 shares of the firm’s stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $64.81, for a total value of $85,484.39. Following the completion of the sale, the insider directly owned 3,126 shares of the company’s stock, valued at $202,596.06. This trade represents a 29.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Christopher Paul German sold 3,817 shares of Rhythm Pharmaceuticals stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $80.75, for a total value of $308,222.75. Following the transaction, the chief accounting officer directly owned 922 shares of the company’s stock, valued at approximately $74,451.50. This represents a 80.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,417 shares of company stock worth $6,352,511. Corporate insiders own 6.10% of the company’s stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.